Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters

Clinical Cancer Research

Volumn 14, Issue 13, 2008, Pages 4292-4297

  Murphy, Christopher K ^a,f   Fey, Edward G ^b   Watkins, Brynmor A ^b   Wong, Vivien ^e   Rothstein, David ^a   Sonis, Stephen T ^c,d  

^a ActivBiotics Inc   (United States)

^b Biomodels LLC

^c HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e Theritas Inc

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICAL; MANGANESEDICHLORO(3,10,13,20,26 PENTAAZATETRACYCLO[20.3.1.0(4,9).0(14,19)] 1(26),22(23),24 HEXACOSATRIENE); PALIFERMIN; PLACEBO; SUPEROXIDE; SUPEROXIDE DISMUTASE; ANTIOXIDANT; ORGANOMETALLIC COMPOUND; OXYGEN;

ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CHEEK POUCH; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; HAMSTER; MUCOSA INFLAMMATION; NONHUMAN; POWDER; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; WORLD HEALTH ORGANIZATION; ANIMAL; CHEMICAL MODEL; CHEMISTRY; DISEASE COURSE; MALE; METABOLISM; NEOPLASM; RADIOTHERAPY; STOMATITIS; SYRIAN HAMSTER;

ANIMALS; ANTIOXIDANTS; CRICETINAE; DISEASE PROGRESSION; FREE RADICALS; MALE; MESOCRICETUS; MODELS, CHEMICAL; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; OXYGEN; RADIATION INJURIES; RADIOTHERAPY; STOMATITIS; SUPEROXIDE DISMUTASE;

EID: 48249114805     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4669     Document Type: Article

References (23)

1. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100:1995-2025.
2. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000;8:33-9.
3. Elting L, Cooksley C, Chambers M, Cantor SB, Manzullo, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003;98:1531-9.
4. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19: 2201-5.
5. Sonis ST. The biologic role for nuclear factor-κB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 2002;13:380-9.
6. Sonis S, Haddad R, Posner M, et al. Gene expression changes in peripheral blood cells provide an insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol 2007;3:289-300.
7. Sonis ST, Scherer J, Phelan S, et al. The gene expression sequence of radiated mucosa in an animal mucositis model. Cell Prolif 2002;35:93-102.
8. Siomek A, Tujakowski J, Gackowski D, et al. Severe oxidatively damaged DNA after cisplatin treatment of cancer patients. Int J Cancer 2006; 119:2228-30.
9. 2), superoxide dismutases, and related matters. J Biol Chem 1997;272:18515-7.
10. Guo H, Seixas-Silva JA, Jr., Epperly MW, et al. Prevention of radiation-induced oral cavity mucositis by plasmid/liposome delivery of the human manganese superoxide dismutase (SOD2) transgene. Radiat Res 2003;159:361-70.
11. Üçüncü H, Ertekin MV, Yörük Ö, et al. Vitamin E and L-carnitine, separately or in combination, in the prevention of radiation-induced oral mucositis and myelosuppression: a controlled study in a rat model. J Radiat Res (Tokyo) 2006;47:91-102.
12. Valencia J, Veilla C, Urpego A, et al. The efficacy of orgotein in the treatment of acute toxicity due to radiotherapy on head and neck tumors. Tumori 2002;88: 385-9.
13. Esco R. Valencia J, Coronel P, CarcellerJA, Gimeno M, Bascón N. Efficacy of orgotein in the prevention of late side effects of pelvic irradiation: a randomized study. Int J Radiat Oncol Biol Phys 2004;60:1211-9.
14. Menander-Huber KB, Edsmyr F, Huber W. Orgotein (superoxide dismutase): a drug for the amelioration of radiation-induced side effects. Urol Res1978;6:255-7.
15. Suntharalingam M, Jaboin J, Taylor R, et al. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Semin Oncol 2004;31:2-7.
16. Lalla RV, Peterson DE. Treatment of mucositis, including new medications. CancerJ 2006;12:348-54.
17. DiNapoli MD, Papa F. M-40403 Metaphore Pharmaceuticals. IDrugs 2005;8:67-76.
18. Muscoli C, Cuzzocrea S, Riley DP, et al. On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br J Pharmacol 2003;140:445-60.
19. Sonis ST, Tracey C, Shklar G, Jenson J, Florine D. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Path 1990; 69:437-443.
20. Alvarez E, Fey EG, Valax P, et al. Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clin Cancer Res 2003;9:3454-61.
21. Schuster MW, Anaissie E, Hurd D, et al. Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single dose velafermin (CG53135-05) for the prevention of oral mucositis. J Clin Oncol (Meet Abstr) 2006;24:6537.
22. Stiff PJ. Oral mucositis therapy comes of age. J Support Oncol 2005;3:73-5.
23. Chappie IL. Reactive oxygen species and antioxidants in inflammatory diseases. J Clin Periodontol 1997;24:287-96.